Tang Capital Management LLC purchased a new stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,300,000 shares of the company's stock, valued at approximately $7,697,000. Tang Capital Management LLC owned approximately 9.69% of ESSA Pharma at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BML Capital Management LLC acquired a new position in ESSA Pharma in the fourth quarter valued at approximately $7,557,000. Altium Capital Management LLC purchased a new stake in shares of ESSA Pharma during the fourth quarter worth approximately $2,556,000. Bank of America Corp DE lifted its stake in shares of ESSA Pharma by 10,153,775.0% in the fourth quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock worth $1,454,000 after buying an additional 812,302 shares in the last quarter. Aldebaran Capital LLC purchased a new position in ESSA Pharma in the 4th quarter worth approximately $712,000. Finally, Marshall Wace LLP acquired a new position in shares of ESSA Pharma during the 4th quarter worth approximately $324,000. Hedge funds and other institutional investors own 75.12% of the company's stock.
ESSA Pharma Stock Performance
Shares of EPIX stock traded up $0.02 during trading hours on Friday, reaching $1.68. The company had a trading volume of 5,284 shares, compared to its average volume of 337,485. The stock has a fifty day moving average of $1.65 and a 200-day moving average of $1.70. The company has a market capitalization of $74.57 million, a price-to-earnings ratio of -2.43 and a beta of 1.69. ESSA Pharma Inc. has a 12-month low of $1.40 and a 12-month high of $7.88.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. On average, analysts forecast that ESSA Pharma Inc. will post -0.42 EPS for the current year.
ESSA Pharma Profile
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
